PMID- 28470687 OWN - NLM STAT- MEDLINE DCOM- 20180129 LR - 20221207 IS - 2047-2927 (Electronic) IS - 2047-2919 (Linking) VI - 5 IP - 4 DP - 2017 Jul TI - Correlates and prevalence of hypogonadism in patients with early- and late-onset type 2 diabetes. PG - 739-743 LID - 10.1111/andr.12360 [doi] AB - This study aims to compare the prevalence of hypogonadism between male patients with early-onset type 2 diabetes mellitus (T2DM) and late-onset type 2 diabetes. A total of 122 male patients with early-onset T2DM (diagnosis age 40 years) were recruited from our in-patient department between 1 January 2013 and 28 December 2015. Serum FSH, LH, testosterone, lipid profile, uric acid, HbA1c, and beta-cell function were determined in blood samples. The diagnosis of hypogonadism was based on the levels of LH, FSH, and total testosterone. The mean onset age was 29.86 +/- 6.31 and 54.47 +/- 9.97 years old in the early-onset group and late-onset group, respectively. Compared with late-onset T2DM, those with early-onset T2DM had a higher proportion of new-onset diabetes, were more likely to be obese, and had worse glycemic control, lipid control, and lower sex hormone-binding globulin (SHBG). The prevalence of hypogonadism was much higher in the early-onset group than in the late-onset group (48.0% vs. 26.7%, p < 0.05). The rate of secondary hypogonadism in the early-onset group and late-onset group were 44.3% and 25.0%, respectively (p < 0.05). Obesity, waist circumference, and SHBG were significantly associated with serum total testosterone level in all, early-onset, and late-onset T2DM. Both all and early-onset T2DM groups had positive correlations between total testosterone and fasting C-peptide, total cholesterol, triglycerides, and uric acid. Our results indicate that in a population of admission to a large urban hospital in China, the prevalence of hypogonadism was higher in the patients with early-onset T2DM than that of late-onset T2DM. This prevalence might be attributable to greater obesity, worse lipid control, and lower SHBG levels in those patients. CI - (c) 2017 American Society of Andrology and European Academy of Andrology. FAU - Li, Y AU - Li Y AUID- ORCID: 0000-0002-2429-6657 AD - Department of Endocrinology & Metabolism, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. AD - Nanjing Medical University, Nanjing, China. FAU - Zhang, M AU - Zhang M AD - Department of Endocrinology & Metabolism, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Liu, X AU - Liu X AD - Department of Urology, Putuo District People's Hospital, Shanghai, China. FAU - Cui, W AU - Cui W AD - Department of Endocrinology & Metabolism, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Rampersad, S AU - Rampersad S AD - Department of Endocrinology & Metabolism, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Li, F AU - Li F AD - Department of Endocrinology & Metabolism, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Lin, Z AU - Lin Z AD - Department of Endocrinology & Metabolism, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Yang, P AU - Yang P AD - Department of Endocrinology & Metabolism, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Li, H AU - Li H AD - Department of Endocrinology & Metabolism, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Sheng, C AU - Sheng C AD - Department of Endocrinology & Metabolism, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Cheng, X AU - Cheng X AD - Department of Endocrinology & Metabolism, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. FAU - Qu, S AU - Qu S AD - Department of Endocrinology & Metabolism, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. AD - Nanjing Medical University, Nanjing, China. LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20170503 PL - England TA - Andrology JT - Andrology JID - 101585129 RN - 0 (Biomarkers) RN - 0 (Blood Glucose) RN - 0 (Follicle Stimulating Hormone, Human) RN - 0 (Glycated Hemoglobin A) RN - 0 (Insulin) RN - 0 (Lipids) RN - 0 (Sex Hormone-Binding Globulin) RN - 0 (hemoglobin A1c protein, human) RN - 268B43MJ25 (Uric Acid) RN - 3XMK78S47O (Testosterone) RN - 9002-67-9 (Luteinizing Hormone) SB - IM MH - Adult MH - Age of Onset MH - Aged MH - Biomarkers/blood MH - Blood Glucose/analysis MH - China/epidemiology MH - Cross-Sectional Studies MH - Diabetes Mellitus, Type 2/blood/diagnosis/*epidemiology MH - Follicle Stimulating Hormone, Human/blood MH - Glycated Hemoglobin/analysis MH - Hospitals, Urban MH - Humans MH - Hypogonadism/blood/diagnosis/*epidemiology MH - Insulin/blood MH - Lipids/blood MH - Luteinizing Hormone/blood MH - Male MH - Middle Aged MH - Patient Admission MH - Prevalence MH - Risk Factors MH - Sex Hormone-Binding Globulin/analysis MH - Testosterone/blood MH - Uric Acid/blood OTO - NOTNLM OT - early-onset type 2 diabetes OT - hypogonadism OT - late-onset type 2 diabetes EDAT- 2017/05/05 06:00 MHDA- 2018/01/30 06:00 CRDT- 2017/05/05 06:00 PHST- 2016/08/30 00:00 [received] PHST- 2017/02/16 00:00 [revised] PHST- 2017/02/19 00:00 [accepted] PHST- 2017/05/05 06:00 [pubmed] PHST- 2018/01/30 06:00 [medline] PHST- 2017/05/05 06:00 [entrez] AID - 10.1111/andr.12360 [doi] PST - ppublish SO - Andrology. 2017 Jul;5(4):739-743. doi: 10.1111/andr.12360. Epub 2017 May 3.